CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Molecular Insight Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Molecular Insight Pharmaceuticals, Inc.
160 Second Street
Phone: 617.492.5554p:617.492.5554 Cambridge, MA  02142  United States Ticker: MIPIQMIPIQ
This company ceased filing statements with the SEC on 5/13/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Molecular Insight Pharmaceuticals, Inc. (Molecular Insight) is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. The Company has five clinical-stage candidates in development. Its lead oncology product candidates include Azedra, Onalta, Trofex and Solazed. Azedra and Onalta are being developed for the treatment of neuroendocrine cancers; Trofex is being developed for the detection of metastatic prostate cancer, and Solazed is being developed for the treatment of metastatic melanoma. Its non-oncology product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia (insufficient blood flow to the heart muscle). In May 2011, the Company announced that it filed for bankruptcy under Chapter 11 of the United States Bankruptcy Code.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201012/31/2009YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Joseph M.Limber 59 9/1/2009 9/1/2008
Principal Executive Officer, EVP, CSO, President of Research & Development, Director John W.Babich 53 12/8/2010
President, Chief Restructuring Officer, Director HarryStylli 48 12/8/2010 1/1/2004
6 additional Officers and Directors records available in full report.

Business Names
Business Name
MIPIQ
Molecular Insight Limited

General Information
Number of Employees: 71 (As of 12/31/2009)
Outstanding Shares: 25,268,327 (As of 11/1/2010)
Shareholders: 97
Stock Exchange: OTC
Federal Tax Id: 040562086
Fax Number: 617.871.6983
Email Address: info@molecularinsight.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023